The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.
 
Brian D. Badgwell
No Relationships to Disclose
 
Mariela A. Blum
No Relationships to Disclose
 
Naruhiko Ikoma
No Relationships to Disclose
 
Xuemei Wang
No Relationships to Disclose
 
Jeannelyn Estrella
No Relationships to Disclose
 
Sinchita Roy-Chowdhuri
No Relationships to Disclose
 
Prajnan Das
Honoraria - Amirsys; Meniscus Health Care Communications; Potomac Center for Medical Education
Consulting or Advisory Role - Eisai
Research Funding - Genentech (Inst)
 
Bruce D. Minsky
Other Relationship - American Society for Radiation Oncology; MD Anderson Physician’s Network
 
Shumei Song
No Relationships to Disclose
 
Paul F. Mansfield
Patents, Royalties, Other Intellectual Property - Royalties for up to date
 
Jaffer A. Ajani
Honoraria - Aduro Biotech; Bristol-Myers Squibb; Lilly; Merck
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly